STOCK TITAN

Integra LifeSciences Appoints Jeff Graves, Ph.D., to Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Integra LifeSciences Holdings Corporation (Nasdaq: IART) appoints Jeff Graves, Ph.D., president and CEO of 3D Systems Corporation, to its board of directors. Dr. Graves brings a wealth of experience from leading and transforming technically complex businesses, including his roles at 3D Systems, MTS Systems Corporation, and C&D Technologies, Inc. His expertise in streamlining global operations and delivering differentiated solutions will be valuable to Integra's board and shareholders. With the addition of Dr. Graves, Integra has welcomed four new directors since 2021, signaling a commitment to enhancing the board's expertise and diversity.
Positive
  • None.
Negative
  • None.

PRINCETON, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Jeff Graves, Ph.D., president and chief executive officer of 3D Systems Corporation, was appointed to the company’s board of directors, effective immediately. With the appointment of Dr. Graves, Integra has added four new directors since 2021.

“I am pleased to welcome Jeff to our board of directors. He is a highly-accomplished executive with a track record of leading and transforming technically complex businesses,” said Stuart Essig, chairman of the Integra board of directors. “His experience in streamlining global operations to deliver differentiated solutions to markets, including healthcare, will be valuable assets to the board and enable Integra to continue driving shareholder value.”

Dr. Graves has been the president and CEO of 3D Systems, a leading additive manufacturing solutions provider to industrial and healthcare companies, since May 2020. Prior to joining 3D Systems, he served as CEO, president and director of MTS Systems Corporation, a global supplier of test, simulation, and measurement systems. Previously, Dr. Graves served as president and CEO of C&D Technologies, Inc. He also assumed executive leadership roles at Kemet Corporation as its chief operating officer and subsequently became CEO. Earlier in his career, Dr. Graves held a number of leadership and technical roles at GE, Rockwell Automation and Howmet Corporation. He currently serves on the board of directors of 3D Systems and Hexcel Corporation.

Dr. Graves received his bachelor’s degree in metallurgical engineering from Purdue University and completed his master’s degree and Ph.D. in metallurgical engineering at the University of Wisconsin. He has been recognized with the distinguished alumni award from both universities. He is also a master black belt in six sigma.

About Integra LifeSciences
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Aurora®, Bactiseal®, BioD™, CerebroFlo®, CereLink® Certas® Plus, Codman®, CUSA®, Cytal®, DuraGen®, DuraSeal®, DuraSorb®, Gentrix®, ICP Express®, Integra®, Licox®, MAYFIELD®, MediHoney®, MicroFrance®, MicroMatrix®, NeuraGen®, NeuraWrap™, PriMatrix®, SurgiMend®, TCC-EZ® and VersaTru®. For the latest news and information about Integra and its products, please visit www.integralife.com.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2022, and information contained in subsequent filings with the Securities and Exchange Commission. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Investors:
Chris Ward
(609) 936-2322
chris.ward@integralife.com

Media:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/29a24c89-6c0d-4ab8-89d9-0fee51aacdaa


Jeff Graves, Ph.D., president and CEO of 3D Systems Corporation, was appointed to Integra LifeSciences Holdings Corporation's board of directors.

The ticker symbol for Integra LifeSciences Holdings Corporation is IART.

Jeff Graves has a background in leading and transforming technically complex businesses, including his roles at 3D Systems, MTS Systems Corporation, and C&D Technologies, Inc. He has expertise in streamlining global operations and delivering differentiated solutions to markets, including healthcare.

Jeff Graves received his bachelor’s degree in metallurgical engineering from Purdue University and completed his master’s degree and Ph.D. in metallurgical engineering at the University of Wisconsin. He has been recognized with the distinguished alumni award from both universities and is a master black belt in six sigma.

Integra LifeSciences Holdings Corporation has added four new directors since 2021, including Jeff Graves, Ph.D., president and CEO of 3D Systems Corporation.
Integra Lifesciences Holdings Corp

NASDAQ:IART

IART Rankings

IART Latest News

IART Stock Data

Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Analytical Laboratory Instrument Manufacturing
US
Princeton

About IART

integra lifesciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. integra's orthopedic products include devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. integra is a leader in neurosurgery, offering a broad portfolio of implants, devices, instruments and systems used in neurosurgery, neuromonitoring, neurotrauma, and related critical care. in the united states, integra is a leading provider of surgical instruments to hospitals, surgery centers and alternate care sites, including physician and dental offices. founded in 1989 integra is headquartered in plainsboro, new jersey and has over 3,500 employees worldwide. integra's common stock is li